Loading...
Loading...
Bristol-Myers
Squibb Company
BMY today announced it has entered into a
three-year collaboration agreement with Reckitt Benckiser Group plc
RBGLY for several of its over-the-counter medicines currently sold
across Latin America, primarily in Mexico and Brazil.
Under the terms of the collaboration agreement, Reckitt Benckiser will
pay Bristol-Myers Squibb an upfront payment in the amount of $438
million for the exclusive rights to sell, distribute and market the
following medicines for a three-year period: Picot, an antacid, Tempra,
a pain reliever and fever reducer, Micostatin, an antifungal, and
Graneodin, a cough and cold medicine, sold primarily in Mexico; and
Dermodex, an anti-rash cream, Luftal, an anti-gas medicine, and
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in